A 52-week, open-label, observational study evaluating tolerability, efficacy and physicians satisfaction of rivastigmine oral solution in Alzheimer's disease in Taiwan
一项为期 52 周、开放标签、观察性研究，旨在评估利伐斯的明口服溶液在台湾阿尔茨海默病患者中的耐受性、疗效和医生满意度。
期刊:Journal of Alzheimers Disease Reports
影响因子:2.8
doi:10.1177/25424823241311860
Lee, Chuo-Yu; Wang, Wen-Fu; Hsu, Jung-Lung; Yang, Yuan-Han; Jhang, Kai-Ming
